Micrograph of serous carcinoma. Credit: Ed Uthman.

MaxCyte has dosed the first patient in a Phase I clinical trial to evaluate the safety and effectiveness of intraperitoneal infusions of MCY-M11 for the treatment of advanced ovarian cancer and peritoneal mesothelioma.

The multi-centre, non-randomised, open-label, dose-escalation trial intends to enrol around 15 subjects across two clinical sites in the US, including National Cancer Institute at National Institutes of Health (NIH) and Washington University.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

It will include women with platinum-resistant, high-grade serous adenocarcinoma of the ovary, primary peritoneum or fallopian tube, or subjects with advanced peritoneal mesothelioma with recurrence after prior chemotherapy.

The trial will feature four experimental cohorts with three to six subjects in each of the cohorts.

“In recent years we have seen tremendous progress in the treatment of some types of cancer, but there remains a significant need to explore novel treatments that may benefit patients.”

The primary objective of the trial is the incidence and severity of adverse events as measured by Common Terminology Criteria for Adverse Events v.5.0 (CTCAE v.5.0).

The trial’s secondary objectives include response evaluation criteria in solid tumours (RECIST) and immune-related response evaluation criteria in solid tumours (irRECIST).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

MaxCyte chief medical officer Claudio Dansky Ullmann said: “In recent years we have seen tremendous progress in the treatment of some types of cancer, but there remains a significant need to explore novel treatments that may benefit patients.

“Individuals with advanced and relapsed ovarian cancer or peritoneal mesothelioma have limited effective therapeutic options today. MCY-M11 is an exciting new approach with the potential to improve outcomes for these patients.”

MCY-M11 is currently being studied as a chimeric antigen receptor (CAR) therapeutic product candidate.